Design and Synthesis of Some New Quinoxaline-1,2,4-Oxadiazole-Amide Conjugates as EGFR Targeting Agents and ADMET Studies

Abstract

The synthesis of some new quinoxaline-1,2,4-oxadiazole-amide conjugates (6a–n) was described, and their structures were determined using ¹HNMR, ¹³CNMR, and mass spectral analysis. The in vitro anti-cancer activity of the compounds (6a–n) against three human cancer cell lines such as MCF-7 (breast), HepG2 (lung), and DU-145 (prostate) revealed that the compounds 6d, 6e, and 6f exhibited promising activity against three cancer cell lines. Predominantly, compound 6f demonstrated greater activity than the standard drug Etoposide on MCF-7, HepG2, and DU-145 with IC₅₀ values of 0.82 ± 0.01, 1.30 ± 0.02, and 2.12 ± 0.04 µM, respectively. Furthermore, the compounds 6e and 6f displayed promising inhibitory activity over the tyrosine kinase EGFR when compared with the standard Erlotinib. Molecular docking studies carried out on three potent compounds (6d, 6e, and 6f) on the EGFR receptor recommended that the compound 6f strongly binds to protein EGFR (pdbid: 4HJO). In addition, the in silico pharmacokinetic profile was also achieved for the three potent compounds 6d, 6e, and 6f using SWISS/ADME and pk CSM. Results showed that the compounds 6d, 6e, and 6f followed the Lipinski rule, Veber rule, Egan rule, Ghose rule, and Muegge rule without any deviation.

Keywords:

• ADMET studies
• in vitro anti-cancer activity
• molecular docking
• quinoxaline-1,2,4-oxadiazole-amide conjugates
• SARs
• tyrosine kinase EGFR inhibitory activity

Disclosure Statement

No potential conflict of interest was reported by the author(s).